IXI.L

IXICO Plc
IXICO plc - Result of GM, Issue of Equity & TVR
25th October 2024, 11:55
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 7236J
IXICO plc
25 October 2024
 

25 October 2024

 

 

IXICO PLC

 

("IXICO" or the "Company")

 

Result of General Meeting, Issue of Equity and Total Voting Rights

 

IXICO plc (AIM: IXI), the medical imaging advanced analytics company delivering insights in neuroscience, announces that all resolutions put to Shareholders at the General Meeting held earlier today in connection with the placing, subscription and retail offer announced by the Company on 8 October 2024 were duly passed, including the amendment resolutions referred to in the announcement dated 22 October 2024.

 

 

Resolution

For

Against

Withheld

Total votes cast



Number of votes

%

Number of votes

%

Number of votes

 

1

Ordinary resolution to authorise the directors to allot shares

26,857,594

99.97%

8,194

0.03%

37,912

26,865,788

2

Ordinary resolution to approve the Company's EMI Share Option Plan

26,676,840

99.30%

188,448

0.70%

38,412

26,865,288

3

Special resolution to authorise the directors to disapply pre-emption rights

26,827,687

99.86%

38,101

0.14%

37,912

26,865,788

(1)     Any proxy appointments, which gave discretion to the Chairman have been included in the "For" votes total.

(2)     Votes "For" and "Against" any resolution are expressed as a percentage of votes validly cast for that resolution.

(3)     A vote "Withheld" is not a vote in law and is not counted in the calculation of the percentage of shares voted "For" or "Against", nor in the aggregate figure of total votes cast.

 

Issue of Equity and Total Voting Rights

 

Following shareholder approval at the general meeting and conditional on admission, 41,315,792 new ordinary shares have been allotted pursuant to the Placing, 516,244 new ordinary shares pursuant to the Retail Offer and 789,472 pursuant to the Subscription.

 

The Company has therefore allotted a total of 42,621,508 new ordinary shares in connection with the Fundraising.

 

Admission is expected to take place at 8.00 a.m. on or around 28 October 2024.

 

Following Admission, the total number of Ordinary Shares in the capital of the Company in issue will be 92,668,598 with each Ordinary Share carrying the right to one vote. There are no shares held in treasury and therefore, following Admission, the total number of voting rights in the Company will be 92,668,598.

 

The above figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure, Guidance and Transparency Rules.

 

Capitalised terms used in this announcement have the meaning given to them in the announcement of the Placing and Subscription dated 8 October 2024, unless otherwise defined in this announcement.

 

 

For further information please contact:

 

IXICO plc

+44 (0) 20 3763 7499

Bram Goorden, Chief Executive Officer

Grant Nash, Chief Financial Officer

 



 

Cavendish Capital Markets Limited 

(Nominated adviser and sole broker)

+44 (0) 20 7220 0500

Giles Balleny / Dan Hodkinson (Corporate Finance)


Nigel Birks (Life Sciences Specialist Sales)


Harriet Ward (Corporate Broking)


Michael F Johnson / Tamar Cranford Smith (Sales)


 

About IXICO

IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.

 

IXICO has developed and deployed breakthrough data analytics, at scale, through its remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.

 

More information is available on www.IXICO.com and follow us on X (formerly Twitter) @IXICOnews

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOEFLFELIFLEFIS]]>
TwitterFacebookLinkedIn